In Corporate Counsel , Christina Bergeron Discussed New Vermont Law Increasing Private Equity Scrutiny of Health Care Investments - Ropes & Gray LLP

Vermont has enacted new legislation addressing private equity and hedge fund involvement in healthcare investments, marking a significant development in state-level regulatory scrutiny of alternative asset managers in the healthcare sector. According to Christina Bergeron, a partner in the healthcare practice at Ropes & Gray LLP, the Vermont law reflects growing state interest in monitoring private investment activity in healthcare while stopping short of outright ownership restrictions. Bergeron discussed these developments in an analysis of state healthcare transaction laws and their implications for private equity investors and healthcare operators.

The regulatory landscape across U.S. states has become increasingly fragmented. Massachusetts and Minnesota both failed to advance private equity-focused healthcare investment bills during the 2024 legislative session, but Bergeron noted that lawmakers in both states have expressed clear intent to pursue similar legislation in 2025. Pennsylvania represents another jurisdiction where failed 2024 legislation could be revived. This pattern suggests sustained political pressure on private equity healthcare acquisitions at the state level, despite mixed legislative success to date.

California's approach offers a cautionary example for restrictive regulation. Governor Gavin Newsom vetoed a bill that would have required state attorney general approval for certain private equity healthcare acquisitions. Bergeron's analysis indicates that this veto may influence regulatory strategy in other states, with lawmakers potentially opting for less restrictive frameworks to avoid discouraging private equity investment that could strengthen community healthcare infrastructure and services. The tension between protecting healthcare systems from financial engineering and preserving access to PE capital for healthcare modernization thus appears to be reshaping legislative approaches across multiple jurisdictions.

For private equity firms, healthcare operators, and their advisors, the emerging state regulatory environment demands heightened attention to compliance requirements and deal structuring. As of mid-2025, the regulatory pathway remains fluid, with 2025 legislative sessions likely to determine which states advance new restrictions and which adopt more permissive approaches to PE healthcare investment.